These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 29034452)

  • 1. Innovation Incentives and Biomarkers.
    Stern AD; Alexander BM; Chandra A
    Clin Pharmacol Ther; 2018 Jan; 103(1):34-36. PubMed ID: 29034452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker strategy in lung cancer.
    Esencay M; Watson A; Mukherjee K; Hanicq D; Gubernick SI
    Nat Rev Drug Discov; 2018 Jan; 17(1):13-14. PubMed ID: 28959953
    [No Abstract]   [Full Text] [Related]  

  • 3. The future of pharmaceutical manufacturing in the context of the scientific, social, technological and economic evolution.
    Stegemann S
    Eur J Pharm Sci; 2016 Jul; 90():8-13. PubMed ID: 26542345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative business models for drug discovery.
    Bunin BA; Ekins S
    Drug Discov Today; 2011 Aug; 16(15-16):643-5. PubMed ID: 21745585
    [No Abstract]   [Full Text] [Related]  

  • 5. The economics of new drugs: can we afford to make progress in a common disease?
    Hirsch BR; Schulman KA
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives.
    John JE
    Drug Discov Today; 2011 Dec; 16(23-24):999-1000. PubMed ID: 22020052
    [No Abstract]   [Full Text] [Related]  

  • 7. CCGs face legal threat for offering off-label drug for wet AMD.
    Cohen D
    BMJ; 2017 Oct; 359():j5021. PubMed ID: 29089307
    [No Abstract]   [Full Text] [Related]  

  • 8. Antibiotic research and development: business as usual?
    Harbarth S; Theuretzbacher U; Hackett J;
    J Antimicrob Chemother; 2015; 70(6):1604-7. PubMed ID: 25673635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic viability of Stratified Medicine concepts: An investor perspective on drivers and conditions that favour using Stratified Medicine approaches in a cost-contained healthcare environment.
    Fugel HJ; Nuijten M; Postma M
    N Biotechnol; 2016 Dec; 33(6):860-867. PubMed ID: 27664792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic Incentives for Antibacterial Drug Development: Literature Review and Considerations From the Transatlantic Task Force on Antimicrobial Resistance.
    Sciarretta K; Røttingen JA; Opalska A; Van Hengel AJ; Larsen J
    Clin Infect Dis; 2016 Dec; 63(11):1470-1474. PubMed ID: 27578820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should financial incentives be used to differentially reward 'me-too' and innovative drugs?
    Pekarsky B
    Pharmacoeconomics; 2010; 28(1):1-17. PubMed ID: 20014872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The innovative medicines initiative: a European response to the innovation challenge.
    Goldman M
    Clin Pharmacol Ther; 2012 Mar; 91(3):418-25. PubMed ID: 22318619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How artificial intelligence is changing drug discovery.
    Fleming N
    Nature; 2018 May; 557(7707):S55-S57. PubMed ID: 29849160
    [No Abstract]   [Full Text] [Related]  

  • 14. Personalized medicine and economic evaluation in oncology: all theory and no practice?
    Garattini L; Curto A; Freemantle N
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):733-8. PubMed ID: 26289733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers: Delivering on the expectation of molecularly driven, quantitative health.
    Wilson JL; Altman RB
    Exp Biol Med (Maywood); 2018 Feb; 243(3):313-322. PubMed ID: 29199461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ethical Challenges in Biomarker-Driven Drug Development.
    Hey SP
    Clin Pharmacol Ther; 2018 Jan; 103(1):23-25. PubMed ID: 28944956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Why the drug development pipeline is not delivering better medicines.
    Naci H; Carter AW; Mossialos E
    BMJ; 2015 Oct; 351():h5542. PubMed ID: 26496934
    [No Abstract]   [Full Text] [Related]  

  • 18. Medicines for tropical diseases; support through tax-incentives.
    John JE
    Drug Discov Today; 2011 Feb; 16(3-4):91-2. PubMed ID: 21111059
    [No Abstract]   [Full Text] [Related]  

  • 19. Countries mull over incentives for developing antibiotics.
    Anderson T
    Lancet; 2016 May; 387(10031):1894-5. PubMed ID: 27203638
    [No Abstract]   [Full Text] [Related]  

  • 20. Personalized therapeutics and companion diagnostics: a new paradigm in testing and treatment.
    Heger NE; Kellogg MD
    Clin Chem; 2014 May; 60(5):795-6. PubMed ID: 24778305
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.